aXichem AB (publ), publishes its report for the first quarter 2026 on Thursday 21 May 2026. Friday 22 May 2026 at 3:00 p.m., the company invites you to a live web conference with CEO Torsten Helsing.
After the conference, there will be a question-and-answer session. Please note that the presentation is held in Swedish. It is possible to follow the conference via computer or mobile devices.
To register for the web conference, please register via the following link:
https://us06web.zoom.us/webinar/register/WN_0IWMosHyQbOAFNGUqGTtHw
The number of seats is limited, so we recommend registering well in advance to secure a seat. After the conference, the teleconference and the presentation material will be available on the company's website, www.aXichem.com and on the Västra Hamnen Corporate Finance channel on YouTube.
The information was submitted, through the care of the contact person below, for publication on
19 May 2026, at 16:30 CET.
Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: ingredient in animal feed for poultry and ruminants, ingredient in dietary supplements for intestinal health, weight control, sports and exercise, and as an ingredient in dietary supplements for bioavailability enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB. More information is available at www.axichem.com.